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Introduction
Heparin-induced thrombocytopenia (HIT) is an iatrogenic complication of heparin therapy caused by antibodies that recognize complexes formed between heparin and the endogenous protein, Platelet Factor 4 (PF4) (1) (2) (3) . Approximately half of affected patients develop limb-or life-threatening thrombosis (4) (5) (6) . Management involves careful monitoring of platelet counts, a high index of clinical suspicion, cessation of heparin exposure, and the introduction of alternative anticoagulants (7, 8) . These measures have reduced the incidence of new thromboembolic complications, but have had less impact on the incidence of amputations and death (9, 10) . Heparin remains an important anticoagulant in widespread use, and studies that help define the pathophysiology of HIT may lead to better identification of patients at risk and to more targeted intervention strategies.
The antibody response in HIT is unusual in several respects. First, the major complications of HIT are related to thrombosis in contrast to other drug-induced thrombocytopenias (11) . This high incidence of thrombosis may be related in part to the ability of HIT antibodies to activate platelets via FcγRIIA (12, 13) . In a murine model of HIT, only mice with platelets that expressed both human (h) PF4
and FcγRIIA developed thrombocytopenia and thrombosis when given an antiheparin:PF4 monoclonal antibody (mAb) KKO (14) . A second unusual feature is the surprisingly high incidence of anti-heparin:PF4 antibodies in heparinized patients, exceeding a quarter to half of all exposed patients in some settings (15) (16) (17) . Why only a small portion of these patients develop HIT is not clear and no unequivocal differences between the vast majority of individuals who remain asymptomatic and the small number who develop HIT have been identified, although differences in immunoglobulin (Ig) G titers have been noted (18) (19) (20) (21) . A third characteristic of HIT antibodies (including KKO) is that they bind optimally to heparin:PF4 complexes over a narrow molar ratio in vitro (1) (2) (3) 22) . In the case of unfractionated heparin, PF4 forms ultralarge complexes (ULC) of >670 kDa at only.
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It is not known whether similar complexes between PF4 and cell surface glycosaminoglycans (GAGs) form on the surface of platelets or how heparin affects surface complex formation and antigenicity. Based on the knowledge that PF4 can bind to diverse anionic polysaccharides (24) , it may form similar antigenic complexes on platelets by binding to GAGs on the surface of platelets independent of heparin. The composition of these antigenic complexes and their capacity to be modulated has not been studied. We examined the effect of the anti-PF4/heparin mAb KKO (and in some studies, HIT-IgG) on platelets expressing varied amounts of endogenous or exogenous PF4 on their surface both in vitro and in vivo. The results of these studies provide insight into the importance of the level of surface PF4 expression, the effect of heparin on formation of surface antigenic complexes, and potential new diagnostic and therapeutic approaches to HIT based on these new insights.
only.
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Material and Methods
Preparation of recombinant WT hPF4.
Wildtype (WT) human (h) PF4 in pT7-7 plasmid was expressed in BL21DE30 pLysS bacteria, purified, and characterized as described (25) . Recombinant protein was isolated from bacterial lysate supernatant by affinity chromatography using a HiTrap Heparin HP column (Amersham Bioscience). Proteins were purified further by FPLC using a RESOURCE®RPC column (Amersham Bioscience). Protein purity was assessed by 15% (wt/vol) sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) followed by silver staining (26) . Samples were subjected to immunoblotting after electrotransfer to polyvinylidenedifluoride (PVDF) membranes using rabbit anti-hPF4 polyclonal antibody (PeproTech), followed by donkey anti-rabbit secondary antibody conjugated to horseradish peroxidase (HRP) (Jackson ImmunoResearch Laboratories) and developed using the ECL kit (PerkinElmer Life Sciences).
Total protein concentrations were determined using the bicinchoninic acid assay (Pierce) as per manufacturer with BSA as standard.
Monoclonal antibodies and HIT immunoglobulins.
KKO, the anti-hPF4 specific mAb RTO and isoimmune control TRA are all mouse IgG2b mAbs (27). Antibodies were fluorescein isothiocyanate (FITC) labeled using a E-Z FITC labeling kit (Pierce) as per the manufacturer.
Monoclonal anti-human CD41a PerCP-Cy5 and anti-mouse CD-41 phycoerythrin (PE) antibodies and Annexin V-PE were from Pharmingen. Polyclonal IgG was isolated from the plasma of 4 patients with clinical HIT (7, 8, 11, 28) Total immunodetectable platelet hPF4 was determined using murine platelets completely deficient in murine PF4 (mPF4 null (29) Samples were washed with PBS, and platelets were lysed in NuPage LDS Sample Buffer (Invitrogen). Fractions were separated on a 10% SDS-PAGE gel and immunoblotted after electrotransfer to a PVDF membrane with a rabbit antihuman PF4 (1:5,000) primary antibody (PeproTech) followed by an HRPconjugated donkey anti-rabbit antibody (Jackson ImmunoResearch Laboratories) and developed using an ECL kit. Autoradiograpic bands over the linear range of exposure were analyzed on a UMAX Vista-58 scanner, and the data analyzed by developing a histogram of the calculated density using the NIH program ImageJ (rsb.info.nih.gov). Total surface PF4 binding was also detected using mPF4 null platelets after paraformaldehyde crosslinking, as above. Samples were then washed 3x with Tyrode's buffer and incubated with polyclonal rabbit anti-hPF4 
Characterization of transgenic mice.
Transgenic mice expressing different amounts of hPF4 mRNA per platelet have been described previously (26) . Three lines bearing 1, 6 and 22 copy numbers of the human PF4 gene/haplotype were used. Previous analysis of multiple tissues using immunohistochemistry and RT-PCR showed that hPF4 was expressed exclusively in megakaryocytes. Transgenic mice expressing FcγRIIA were generously provided by Steven McKenzie, Thomas Jefferson University (30) and crossbred with these hPF4 mice. All murine lines were backcrossed onto the C57BL/6J background >8 times. Genomic makeup of mice was determined by PCR analysis using oligonucleotide primers described previously (26, 30) . Controls included littermates transgenic for hPF4 or FcγRIIA only. Mice were 6-10 weeks of age at the time of study.
Total platelet hPF4 levels in the various transgenic hPF4 lines were determined using an Asserachrom PF4 kit (Diagnostica Stago) as per the manufacturer using recombinant hPF4 as the standard. Complete blood counts were measured in 50 µl of whole blood obtained by retroorbital puncture into Safe-T-Fill ® minicapillary blood collection tubes (Kabe Labortechnik). Platelets were enumerated using an automatic cell counter (HEMAVET, Drew Scientific).
In the therapeutic intervention studies, either porcine heparin (100 U/kg) or protamine sulfate (2 mg/kg) were injected IV over 2 mins. KKO (200 µg) was
given IP 1 hr later (zero time point). Injection of heparin or protamine was repeated 21 and 45 hr later. Blood counts were determined as above.
Statistics.
Platelet counts between groups were compared using the Student's t-test.
Statistical analyses were performed using Graph Pad Prism (Graphpad Software). Differences were considered significant at a p value of < 0.05.
Results
PF4 bound to the platelet surface forms antigenic complexes on human platelets.
To better understand the pathogenesis of HIT, we asked whether antigenic complexes form between PF4 and GAGs on the platelet surface. KKO bound poorly to unstimulated, washed human platelets (Fig. 1A) . However, addition of recombinant hPF4 markedly increased binding of KKO in a dose-dependent manner. Binding followed a bell-shaped curve (Fig. 1A) . Maximal binding of KKO, corresponding to an ~100-fold increase in fluorescence intensity, occurred at an hPF4 concentration of 50 µg/mL. This peak was not limited by the amount of KKO added (data not shown). Binding of an isotype control mAb TRA and anti-CD41 mAb increased <7% compared with KKO over the same range of PF4 concentrations (Fig. 1A) .
We next examined the effect of heparin on the binding of KKO to surface-bound PF4. Platelet GAGs are composed predominantly of chondroitin and, to a lesser extent, heparan sulfates (31), each of which has a lower affinity for PF4 than HMW heparin (32) . At levels of added PF4 where binding of KKO to platelets is suboptimal (left side of the curve in Fig 1B) . These studies suggest that in settings associated with high levels of surface-bound PF4, heparin enhances cell surface antigenicity.
Binding of KKO to PF4-coated platelets induced their activation as measured both by an increase in surface binding of Annexin V (Fig. 1C ) and expression of P-selectin (data not shown). We then asked whether activation releases only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From additional PF4 from internal stores, which in turns alters the composition of GAG:PF4 complexes and KKO binding. To examine this possibility, we incubated human platelets with 50 µg/mL of hPF4 and followed KKO binding over time. KKO binding increased with time, reaching a plateau at 20 to 60 min and then decreased (Fig. 1D) . These dynamic changes suggest that the composition of the surface GAG:PF4 complexes had been modified over time, possibly due to release of PF4 from newly recruited FcγRIIA-activated platelets (14) . As additional PF4 is incorporated into these complexes, the optimal ratio is exceeded and antibody binding is impaired.
PF4 bound to the platelet surface forms antigenic complexes on murine platelets.
Studies of human platelets are thus confounded by the release of internal stores of hPF4 and the presence of FcγRIIA on their surface. We, therefore, switched to murine platelets that naturally lack the FcγRIIA platelet receptor, and studied KKO binding to surface of mPF4 null platelets (29) . Addition of hPF4 lead to a near-doubling in total platelet PF4 for each doubling of hPF4 in the media over the range studied ( Fig. 2A , open diamonds) with a slightly blunted, but similar, proportional increase in total surface immunogenic PF4 detected using a polyclonal anti-hPF4 antibody ( Fig. 2A, grey squares) . Under similar conditions, binding of KKO to murine platelets followed the same bell-shaped curve seen with human platelets ( Fig. 2A , black circles).
We then examined whether KKO recognized PF4 bound to surface GAGs by pre- (Fig. 2C) . However, IV.3 did reduce the total amount of KKO that bound to FcγRIIA + platelets only (Fig. 2C) , suggesting the presence of the FcγRIIA receptor may also provide stability to bound KKO.
Platelet activation by KKO clearly leads to platelet activation via FcγRIIA engagement, as WT murine platelets are minimally activated, as measured by the binding of Annexin V (Fig. 2D) . We then studied the effect of platelet activation on KKO binding using murine platelets that were double transgenic for high levels of hPF4 and FcγRIIA, hPF4 High /FcγRIIA + (+/+ in Fig. 2E ), compared to hPF4 High /FcγRIIA -platelets (+/-in Fig. 2E ). hPF4 High /FcγRIIA + and hPF4 High / FcγRIIA -platelets bound the same amount of KKO at time zero. However when
FcγRIIA was expressed, binding of KKO increased greatly over time (Fig. 2E) . A much smaller increase was also seen for the binding of RTO, a mAb that binds to hPF4 independent of heparin (27) (Fig. 2E) . These studies support the concept that platelet activation via FcγRIIA releases additional PF4 that becomes incorporated within antigenic complexes recognized by KKO.
Studies with HIT IgG.
KKO competes with many HIT antibodies for binding to platelets, suggesting a common epitope on heparin:PF4, and activates platelets through similar mechanisms (27). Nevertheless, we extended our studies to determine whether HIT antibodies behaved in a similar manner with respect to platelet surface PF4 levels. Studies based on those shown in Fig. 1A were repeated using either IgG only.
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isolated from patients with HIT diagnosed by clinical criteria (7, 8, 11, 28) (Fig. 3A) in contrast to the four normal controls or a commercial IgG preparation (Fig. 3B) . Maximal platelet activation occurred at the same concentration of PF4 (50 µg/mL) as was seen with KKO.
In vivo studies in mice expressing different amounts of hPF4.
The in vitro data indicate that there is an amount of cell surface PF4 at which HIT-antibody binding is maximal. This bell-shaped relationship between PF4 concentration and binding of HIT antibody extends previous studies in which a similar relationship was seen when the concentrations of PF4 and heparin in solution were varied (22) . However, GAGs appear to fulfill the role of heparin on the platelet surface. If these findings have clinical relevance, then in a murine model of HIT: 1) the severity of thrombocytopenia should parallel endogenous hPF4 expression, 2) if sufficient PF4 has already been released and bound to the cell surface, exogenous heparin would not be required to cause thrombocytopenia once antibody is present, and 3) heparin would exacerbate thrombocytopenia in the setting of high PF4 content.
We previously described the creation of transgenic mouse lines expressing various levels of hPF4 RNA (26) . We now measured total platelet hPF4 compared to the average hPF4 content of 4 human platelet controls. hPF4 levels varied from ~0.5 times the content of human platelets in hPF4
Low mice (which have 1 copy of the hPF4 transgene/haploid genome) to ~2 times the level in hPF4 Mid mice (which have 6 copies/haploid genome) to ~6 times in hPF4 High mice (which have 22 copies/haploid genome) (Fig. 4A) . Flow cytometric studies of platelets from these transgenic lines demonstrate that all have detectable surface-bound hPF4 in vivo measured 10 mins after IV injection of KKO, with antibody binding proportional to platelet PF4 expression (Fig. 4B) .
By 3 hr after an IP injection of KKO, hPF4
High /FcγRIIA mice developed severe, antibody dose-dependent thrombocytopenia, which persisted for >7 days (Fig.   5A ). Mice that were hPF4 High or FcγRIIA alone did not develop thrombocytopenia (Fig. 5A) . The severity of thrombocytopenia correlated with the dose of injected antibody. Thrombocytopenia was not seen with an equivalent amount of the isoimmune control TRA or RTO (Fig. 5B) . The severity of the thrombocytopenia also correlated with the genetically determined level of hPF4 (Fig. 5C ). Daily injections of 20 U of SQ heparin into hPF4 Mid /FcγRIIA mice as used in the previously described HIT murine model (14) did not lower the initial nadir platelet count further, but did prolong the duration of severe thrombocytopenia for >2 weeks ( Fig. 5D and data not shown). There was no unexpected loss of animals in these studies, although specific histological studies for thrombotic events were not pursued.
Therapeutic intervention in the murine model.
The above studies suggest that interventions that skew the GAG:PF4 ratio towards either extreme may protect against formation of HIT antigenic complexes on the platelet surface. We employed two such strategies to test this hypothesis:
1) Based on the data in Fig. 1B , we inferred that a marked excess of heparin would reduce surface antigenicity and prevent HIT even in the presence of a pathogenic anti-PF4/heparin antibody.
2) The data suggest a similar outcome would be expected from an excess of a cationic moiety that binds to platelets and prevents incorporation of PF4 into the antigenic complexes. Protamine sulfate is a small positively-charged molecule that competes with PF4 for binding to GAGs (33) and has been used clinically to neutralize heparin (34) . Although cardiovascular side-effects have been reported rarely (35, 36) , it has the advantage over infusing large amounts of hPF4 by not chancing a transient increase in surface antigenicity.
Transgenic hPF4
Mid /FcγRIIA mice were given an IV infusion of either 100 U/kg of unfractionated heparin or 2 mg/kg protamine sulfate 1 hr prior to an IP injection of 200 µg of KKO. Both prevented thrombocytopenia at 3 hr and decreased the severity of thrombocytopenia at 24 hr (Fig. 6A) . Repeat doses given on the second and third days maintained platelet counts above the level in mice that had received KKO alone. In hPF4 High /FcγRIIA mice, these treatment regimens gave different results ( Fig. 6B ): High-dose heparin was ineffective in preventing KKO-induced thrombocytopenia. In contrast, platelet counts were significantly higher in protamine sulfate-treated mice than in mice receiving antibody alone at 24 and 48 hr.
Discussion
Surface-bound PF4 is antigenic for HIT antibodies and KKO over a narrow range of PF4 concentrations, leading to platelet activation through FcγRIIA. Our data suggest that PF4 forms antigenic complexes with endogenous GAGs on the surface of platelets similar to ULCs that form between HMW heparin and PF4 in solution (23) . These data could explain why only a subgroup of heparinized patients with HIT antibodies develop HIT. Platelets vary widely in PF4 content (unpublished data) and perhaps in released PF4 and surface PF4 levels. Those individuals with the highest levels of surface PF4 prior to heparinization may be most susceptible to continue to express surface HIT antigenic complexes after heparinization and develop HIT. In addition, the proposed model may also help explain why HIT can develop after heparin therapy has been stopped (37) and why HIT can occur in a delayed fashion long after infused heparin has been cleared (38) .
PF4 is a member of the CXC subfamily of chemokines that possesses high affinity for heparin and other large, anionic molecules (39) . PF4 is expressed in megakaryocytes and stored in platelet α-granules from which it is released upon activation (40, 41) . After its release, PF4 binds to GAG on vascular cell surfaces (42) . HIT IgG and the mAb KKO bind to Chinese Hamster Ovarian (CHO) cells in the presence of exogenous PF4, but not to CHO cells lacking heparan sulfateor chondroitin sulfate-containing proteoglycans (27). Similarly, these antibodies bind directly to monocytes (43) and cultured endothelial cells (44) , and binding is reduced by pretreating with heparanases (44) . Under certain experimental circumstances, heparin has been shown to promote the binding of HIT IgG and KKO to activated platelets, which acts in a feed-forward manner to perpetuate platelet activation and more IgG binding (22, 45) .
The concentration of PF4 that optimized KKO platelet binding (50 µg/mL) is the same as proved optimal for activation by HIT IgG (Figs. 1A and 3A, respectively) , (46) , so that the conditions we analyzed are achievable in vivo.
To study the in vivo relevance of our observation, we used the previously described murine HIT model (14) . We, as others, had assumed that heparin would be a necessary component for thrombocytopenia to develop in this model. Based on our findings, we reasoned that we could interfere with the development of thrombocytopenia in the double-transgenic mice by altering the surface GAG:PF4 ratio on the platelets. In support of this concept, infusing either high doses of heparin or protamine sulfate prevented KKO-induced thrombocytopenia in hPF4
Mid /FcγRIIA mice (Fig. 6 ). In the hPF4 High /FcγRIIA mice, the same heparin dose was ineffective, in contrast to the protamine sulfate, which retained its efficacy (Fig. 6) . The dose of heparin we used is often exceeded in clinical settings (48), and we have used higher doses of both agents safely in mice (29) .
However, these interventions were intended to test our model and the role of only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From surface platelet PF4 in HIT antigenicity. Moreover, we have yet to determine whether similar strategies can reverse established thrombocytopenia or thrombosis. Clinically, direct thrombin inhibitors block the explosive amplification of thrombin on platelet activation and coagulation, but have not eliminated the occurrence of amputations and death in affected patients. It is possible that antibody-mediated platelet activation promotes thrombosis through additional mechanisms involving platelet adhesion to the vasculature (49) and plateletleukocyte aggregation (50) that would be better addressed by an intervention that acts proximal to thrombin generation. Thus, we envisage similar strategies to those in Fig. 6 that could target these proximal HIT mechanisms and be used in combination with direct thrombin inhibitors.
In Fig. 7 , we propose a model for the onset of HIT based on our findings and on published literature. Patients who develop HIT are typically older and likely to have underlying cardiovascular disease and/or have undergone surgical manipulation. We propose that platelet activation in these patients leads to PF4 release and rebinding. In the vast majority of individuals and clinical settings, endogenous PF4 is low and surface PF4 expression does not exceed the equivalent of adding 50 µg/mL of PF4 (Fig. 7, left) . Therapeutic heparinization markedly reduces platelet surface PF4. Heparinization would induce HIT antibody formation in up to half of these patients, but there would be little surface HIT antigen available and little risk of developing HIT. On the other hand, in the small number of individuals with high platelet PF4 content and sufficient platelet activation leading to high surface PF4 levels, therapeutic heparinization would not eliminate surface antigenicity (Fig. 7, right) . These patients are at least as likely as other patients to develop HIT antibodies after heparinization. However in these individuals, the antibodies can activate a large number of platelets because of the high level of remaining platelet surface antigen, leading to more PF4 release and repetitive cycles of platelet activation. These patients are at high risk to develop HIT. The model we propose offers the testable hypothesis that patients with high total and/or surface PF4 are at significant risk of developing HIT, and that they can be identified prospectively and offered alternative management. Identifying such high-risk patients will require additional studies to measure HIT antigen using an antibody like KKO and studying its binding in the presence of heparin (Fig. 1B) or subsequent to platelet activation (Fig. 1C) .
Our studies and model focus on the events on the platelet surface, but there is little reason to suppose that similar events are not concurrently happening on the surface of the endothelial lining, circulating monocytes and other vascular cells.
The binding of HIT antibodies to the PF4 antigenic complexes on these cells would not only contribute to the developing thrombocytopenia, but also to the inflammatory state and to the thrombosis by expressing tissue factor and releasing procoagulant microparticles accelerating thrombin formation, that are recognized components of HIT (51) (52) (53) .
Finally, we believe that surface PF4 may have a biological role as well. We have previously shown that platelet PF4 content affects thrombogenicity in a bellshaped curve fashion (29) . We propose that both thrombogenicity and HIT antigenicity are greatest when formation of stable, GAG:PF4 ULCs on cell surfaces is maximal. How such complexes contribute to thrombosis needs further study, but if true, patients whose platelets retain surface antigenic ULC after heparinization are not only targets for HIT antibodies, but are also intrinsically prothrombotic. Each experiments was performed three times, each in triplicate. In (E), a study representative of three is shown. only.
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